RNA — Atrium Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2093101 ·
Last close
$6.48
Market Cap
$139.78M
52W High
$16.77
52W Low
$6.36
ADV30
234,797
Next earnings
2026-11-12
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California. Atrium Therapeutics, Inc. was formerly a subsidiary of Avidity Biosciences, Inc.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 15,321,000 — -6,629,000 -4,266,000 263,985,000 44,565,000 58,967,000
Jun 2026 3,004,000 — -22,618,000 -20,186,000 280,512,000 72,334,000 65,936,000
Mar 2026 19,635,000 — -17,280,000 -16,633,000 292,360,000 267,849,000 58,256,000
Dec 2025 859,000 — -48,035,000 -48,069,000 278,353,000 270,000,000 71,066,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-53,188,000
Investing CF
$-194,864,000
Financing CF
$320,803,000
CapEx
$-3,313,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.34
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-8,058,000
Inventory
—
Receivables
$15,000,000
ST Investments
$191,566,000
EBIT TTM
$-96,396,000
Pretax Income TTM
$-93,317,000
Interest Exp TTM
—
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$38,819,000
EBITDA
$-74,661,000
Free Cash Flow
$-60,449,124
Enterprise Value
$-69,392,984
Total Cash
$232,074,000
Total Debt
$679,000
Shares Out
21,571,507
Trailing EPS
$-5.22
Book Value
$12.50
ROE
-95.0%
ROA
-34.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 18,618,000 -76,814,000 -76,684,000 278,353,000 71,066,000 207,287,000 -41,129,000
Dec 2024 10,897,000 -13,218,000 -25,122,000 7,186,000 68,294,000 -61,108,000 -22,553,000
Dec 2023 9,764,000 -6,386,000 -6,385,000 10,293,000 80,912,000 -70,619,000 56,390,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$280,512,000
Forward EPS
$-5.96

Peers — same industry

TickerNameMarket CapLastDaily %
ALXO ALX ONCOLOGY HOLDINGS INC $138.97M $1.00 —
SION Sionna Therapeutics, Inc. $138.87M $3.07 —
MENS Jyong Biotech Ltd. $133.62M $1.80 —
ZNTL Zentalis Pharmaceuticals, Inc. $146.42M $1.49 —
VRXA Veraxa Biotech AG - Post de-SPAC $147.06M $1.04 —

News headlines (Yahoo Finance, 1h cache)

Atrium Therapeutics Reports Third Quarter 2026 Financial Results
2026-11-12 21:10 · Yahoo
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
2026-11-02 11:30 · Yahoo
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
2026-10-27 10:30 · Yahoo
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-10-20 21:23 · Yahoo
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
2026-10-20 12:09 · Yahoo
Atrium Therapeutics Announces $50 Million Private Placement
2026-10-08 10:30 · Yahoo
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real
2026-09-06 10:44 · Yahoo
Atrium Therapeutics to Participate in Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
2026-08-13 20:44 · Yahoo
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation
2026-05-28 10:24 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.